Skip to main content

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is an American commercial-stage biopharmaceutical company focused on developing topical dermatological treatments. The company formulates and commercializes topical therapies using its proprietary formulation technology, featuring its lead product Zoryve for plaque psoriasis and seborrheic dermatitis. Principal revenues derive from commercial sales of prescription dermatological creams and foams to pharmaceutical wholesalers and specialty pharmacies. Core end markets encompass dermatology clinics, outpatient medical facilities, and prescription consumers across the United States. Arcutis Biotherapeutics holds a prominent market position as a developer of innovative topical PDE4 inhibitors for inflammatory skin conditions. The company is headquartered in Westlake Village, California, and its common stock trades on the Nasdaq Global Select Market.

8 of the funds FundTelligence covers report a position in Arcutis Biotherapeutics.

Legal name
Arcutis Biotherapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
8

Funds holding Arcutis Biotherapeutics

Loading...